Acute severe alcohol withdrawal and delirium tremens: CIWA-Ar, benzodiazepines, and Wernicke

Also known as Alcohol withdrawal · Delirium tremens · DTs · CIWA-Ar · Alcohol withdrawal syndrome · AWS

Alcohol withdrawal syndrome (AWS) = symptoms occurring when a chronic alcohol-dependent person STOPS or REDUCES alcohol intake. SPECTRUM: begins 6-24h after last intake (tremor, anxiety, insomnia, nausea, sweating) → hallucinations (12-24h) → seizures (12-48h, up to 15% of patients) → DELIRIUM TREMENS (DTs — typically around 72h after last intake, occurs in 3-5% of withdrawal patients — confusion, hallucinations, autonomic hyperactivity [tachycardia, hypertension, fever, diaphoresis] — mortality as high as 50% without recognition or prompt treatment). PATHOPHYSIOLOGY: chronic alcohol → BRAIN ADAPTS (downregulates inhibitory GABA receptors + upregulates excitatory NMDA receptors) → when alcohol REMOVED → GABA UNDERACTIVE (loss of inhibition) + GLUTAMATE OVERACTIVE (excessive excitation) → hyperexcitable brain → tremor → seizures → DTs. MANAGEMENT: (1) BENZODIAZEPINES (front-line — restore GABA tone — diazepam/lorazepam — symptom-triggered or fixed-schedule). (2) THIAMINE with or before glucose (prevents Wernicke — ICU day-1 supplementation 200-500 mg IV every 8h). (3) ELECTROLYTE/VITAMIN correction (magnesium 64 mg/kg, folate 400-1000 mcg IV). (4) PHENOBARBITAL 10 mg/kg IV (severe or refractory). (5) SUPPORTIVE (exclude sepsis and co-morbidity, ICU for severe DTs).

high15 referencesUpdated 26 July 202620 min readVerification in progress

Practise this topic

8 MCQs

The one-line answer

Alcohol withdrawal is the brain's revenge for chronic suppression — take the alcohol away and the unmasked glutamate storm produces tremor, seizures, and delirium tremens. The spectrum marches across hours: symptoms typically within 8 hours of cessation (tremor, anxiety — syndrome onset 6 to 24 hours after the last drink), seizures at 12 to 48 hours in up to 15 per cent, and delirium tremens typically around 72 hours in 3 to 5 per cent — confusion, hallucinations, autonomic storm, and mortality as high as 50 per cent without recognition or prompt treatment. The brain has down-regulated GABA and up-regulated NMDA to tolerate chronic alcohol; when alcohol stops, excitation is unopposed. The management has four moves: benzodiazepines first (diazepam or lorazepam, symptom-triggered where possible), thiamine with or before glucose (prevent Wernicke), correct magnesium and the other alcohol-associated vitamin-electrolyte deficits, and phenobarbital 10 mg/kg IV for severe or refractory withdrawal. The mantra: benzos first, thiamine with the glucose, and benzodiazepines — not non-benzodiazepine anticonvulsants — for withdrawal seizures.

^[1]

AWS timeline + severity

Stage	Timing	Symptoms	Management
Minor withdrawal	6-24h (onset)	Tremor, agitation, anxiety, insomnia, nausea, sweating, vomiting, hallucinations, tachycardia, hypertension	Benzodiazepine, fixed-dose or symptom-triggered; give at symptom onset and continue until symptoms subside; thiamine; electrolytes^[8]
Alcoholic hallucinosis	12-24h (2-8%)	Hallucinations with the withdrawal syndrome	Benzodiazepine; supportive care^[7]
Withdrawal seizures	12-48h (up to 15%)	Generalised seizures during withdrawal	Benzodiazepines — seizures RR 0.16 vs placebo; carbamazepine, oxcarbazepine, valproate, gabapentin have less abuse potential but do NOT prevent withdrawal seizures^[6]^[8]
Delirium tremens (DTs)	typically ~72h (3-5%)	Potentially fatal encephalopathy: delirium with agitation, hallucinations, life-threatening autonomic dysfunction	ICU with continuous monitoring; benzodiazepines are the mainstay (diazepam or lorazepam); phenobarbital 10 mg/kg IV for refractory; exclude and treat underlying co-morbid illness incl. infection; severe withdrawal may progress to intubation and mechanical ventilation^[7]^[3]^[4]

^[1]

Management of acute alcohol withdrawal

ASSESS SEVERITY AND PREDICT RISK (CIWA-Ar + PAWSS) — (a) CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised): a validated shortened 10-item scale for clinical quantitation of withdrawal severity — scored repeatedly at the bedside; a benzodiazepine dose is given when the score exceeds the local protocol threshold and the score is repeated after dosing.^[1] (b) SYMPTOM-TRIGGERED DOSING: individualized, scale-guided therapy gave a median treatment duration of 9 vs 68 hours and total chlordiazepoxide of 100 vs 425 mg versus fixed-schedule, with equal efficacy and no difference in seizures or delirium tremens (Saitz, JAMA 1994).^[2] (c) HIGH-INTENSITY-CARE SIGNAL: in a multicentre cohort of 8742 hospitalized adults the odds of progressing to intermediate care or ICU rose above 1.0 once the CIWA-Ar reached 24 — but sensitivity at that cut-point was only 0.12, so treat the trend and the patient, not a single number.^[13] (d) PREDICT, do not just react: PAWSS (Prediction of Alcohol Withdrawal Severity Scale) — 10 items derived from 233 predictive articles — identifies patients at risk of COMPLICATED withdrawal (hallucinosis, withdrawal seizures, DTs) BEFORE symptoms appear; in the pilot (68 medically ill inpatients) sensitivity, specificity, PPV and NPV were all 100% at the threshold score of 4, so a PAWSS of 4 or above should prompt escalated monitoring and prophylaxis.^[14] (e) TIMING: symptoms typically manifest within 8 hours of cessation, peak over 1 to 3 days, and can extend for up to 2 weeks; the syndrome begins 6 to 24 hours after the last intake.^[7]^[8] (f) EXCLUDE mimics: electrolyte abnormalities, trauma in the intoxicated patient, hypoglycaemia, sepsis — work-up includes CBC, metabolic panel, magnesium, and CT brain where indicated.^[7]
BENZODIAZEPINE (FIRST-LINE) — (a) MECHANISM: chronic heavy alcohol downregulates CNS inhibitory GABA receptors and upregulates excitatory NMDA receptors; abrupt cessation leaves excitation unopposed. Benzodiazepines restore GABAergic inhibitory tone and calm the hyperexcitable brain.^[7] (b) EVIDENCE: versus placebo, benzodiazepines reduced seizures RR 0.16 (95% CI 0.04-0.69; Cochrane, 64 trials); in the 149-trial network meta-analysis, fixed-schedule diazepam (OR 0.16, 0.04-0.59), lorazepam (OR 0.19, 0.08-0.45) and chlordiazepoxide (OR 0.21, 0.08-0.53) each beat placebo for incident withdrawal seizures — and only fixed-schedule diazepam reduced incident delirium tremens (OR 0.19, 0.05-0.76).^[6]^[9] (c) AGENTS: benzodiazepines are the mainstay; diazepam and lorazepam are the preferred agents depending on treatment regime and clinical context (e.g. hepatic impairment); no single agent has proven clearly superior.^[4]^[6] (d) DOSING STRATEGY: fixed-dose or symptom-triggered schedules are both recommended — give medication at the onset of symptoms and continue until symptoms subside; symptom-triggered (scale-guided) dosing is favoured because it cuts total dose and treatment duration without losing efficacy.^[8]^[2]
THIAMINE (WITH OR BEFORE GLUCOSE) — (a) WHY: manage hypoglycaemia with CONCURRENT administration of thiamine to prevent Wernicke encephalopathy and subsequent Korsakoff syndrome — glucose given to a thiamine-depleted drinker can precipitate acute depletion.^[7] (b) ICU DOSING: for chronic alcohol use disorder admitted to the ICU, suggested day-1 supplementation is thiamine 200-500 mg IV every 8 hours (with magnesium sulfate and folate — below); abandon the reflexive standard banana bag, whose thiamine content likely fails to optimize CNS delivery.^[10] (c) WHAT DOSE IS OPTIMAL? The only dose-ranging RCT found NO clear benefit of high-dose over intermediate or lower thiamine: at-risk drinkers received 100 mg daily vs 100 mg TDS vs 300 mg TDS for 3 days (N=393) and symptomatic Wernicke patients 100 vs 300 vs 500 mg TDS for 5 days (N=127) with no significant differences in cognitive or neurological outcomes — choose patient-specific dosing and correct magnesium and other B-vitamin deficits.^[11] (d) The Cochrane review confirms thiamine has been the treatment of choice for over 50 years but RCT evidence is INSUFFICIENT to determine dose, frequency, route or duration — do not present any single regimen as proven.^[5] (e) NOTE: if alcoholic ketoacidosis is suspected, dextrose-containing fluids are recommended OVER normal saline (with thiamine on board).^[10]
ELECTROLYTE AND VITAMIN CORRECTION — (a) MAGNESIUM and folate may merit supplementation in these patients: the evidence-based ICU day-1 formula pairs thiamine 200-500 mg IV q8h with magnesium sulfate 64 mg/kg IV (approximately 4-5 g for most adults) and folate 400-1000 mcg IV.^[10] (b) Magnesium and other B-vitamin deficiencies should be considered and corrected when treating Wernicke-Korsakoff syndrome — biochemical cofactors matter as much as the thiamine dose.^[11] (c) There is NO available evidence supporting prescription of a multivitamin in this setting — replace what is deficient, not the kitchen sink.^[10] (d) Check the full electrolyte panel (sodium, potassium, phosphate, glucose) — alcohol-associated deficiencies worsen withdrawal and its complications, and refeeding risk rises once nutrition starts.
PHENOBARBITAL (SEVERE OR BENZODIAZEPINE-REFRACTORY) + ALTERNATIVES — (a) EVIDENCE (RCT): a single IV phenobarbital dose of 10 mg/kg (in 100 mL normal saline) added to a standardized symptom-guided lorazepam-based protocol reduced ICU admission to 8% vs 25% with placebo (95% CI of difference 4-32), with no difference in adverse events.^[3] (b) IMPLEMENTATION: a hospital-wide weight-based IV loading order set (10 or 15 mg/kg) across ED, acute care and ICU was associated with faster symptom resolution (4.2-5.0-point lower daily maximum CIWA-Ar at 24-96 h), 30.1 h shorter treatment duration and 2.2 days shorter time to discharge, with no difference in intubation, restraint or mortality outcomes.^[15] (c) REFRACTORY DTs: phenobarbital, propofol and dexmedetomidine are the options when benzodiazepines fail; barbiturates, ketamine and propofol are alternatives or adjuncts in severe withdrawal, which may progress to intubation and mechanical ventilation.^[4]^[7]
SUPPORTIVE CARE, CO-MORBIDITY AND DISPOSITION — (a) WORK-UP: complete blood count, complete metabolic panel, magnesium level, and CT brain where indicated; actively look for the broad differential — electrolyte abnormalities, trauma in the intoxicated patient, infection, hypoglycaemia.^[7] (b) CO-MORBIDITY: assessment of DT must include screening for underlying medical co-morbidities — liver disease is very common in DT patients and complicates presentation, treatment choice and outcome; never attribute fever or deterioration to withdrawal alone.^[4] (c) SUPPORTIVE: quiet environment, treat agitation pharmacologically, physical restraints only as a last resort; manage hypoglycaemia with concurrent thiamine.^[7] (d) DISPOSITION: severe withdrawal warrants ICU-level care after critical-care consultation; patients needing high-intensity care cannot be reliably identified from a single CIWA-Ar number — serial assessment plus medication exposure (lorazepam-equivalent dose above 15 mg in 24 h also signalled risk in the 8742-patient cohort) guides escalation.^[13] (e) BEFORE DISCHARGE: effective treatment of the withdrawal is only the initial step — long-term success depends on facilitating the patient's entry into ongoing treatment (addiction medicine liaison).^[8]

SAQ — Delirium tremens in the ICU

10 minutes · 10 marks

A 49-year-old man with chronic alcohol dependence (1 bottle of spirits/day) is admitted 60 hours after his last drink following a seizure at home. He is grossly tremulous, agitated, hallucinating (seeing insects on the wall), diaphoretic, HR 142, BP 184/105, temp 39.1°C, RR 30, GCS 13, with Mg²⁺ 0.45 mmol/L, K⁺ 2.9 mmol/L, phosphate 0.5 mmol/L, CK 4,200 U/L, and a CIWA-Ar of 27. His wife gave him a dextrose-containing IV fluid in the ambulance.

^[1] ^[2] ^[3] ^[6] ^[7] ^[8] ^[10] ^[13]

SAQ — Wernicke encephalopathy and refractory withdrawal

10 minutes · 10 marks

A 56-year-old malnourished woman with alcohol cirrhosis (Child-Pugh B) is admitted in severe AWS. Despite 80 mg of IV diazepam in 4 h she remains severely agitated, tremulous and has developed nystagmus, lateral rectus palsy and a wide-based gait when she tries to stand. The team has just prescribed a 5% dextrose infusion for rehydration.

^[5] ^[7] ^[10] ^[11] ^[12] ^[3] ^[15] ^[6]

Clinical pearls

High-yield alcohol withdrawal points for CICM/FFICM exam

The pathophysiology in one sentence — GABA down, glutamate up. Alcohol acts as a CNS depressant through GABA activation; chronic heavy use downregulates CNS inhibitory GABA receptors and upregulates excitatory NMDA receptors. On discontinuation the imbalance produces CNS hyperexcitability — the clinical syndrome of withdrawal. This is why benzodiazepines (restoring GABAergic tone) are first-line and why NMDA-active drugs such as ketamine appear as alternatives in severe withdrawal.^[7]
Delirium tremens — around 72 hours, 3 to 5 per cent of withdrawal patients, mortality up to 50 per cent untreated. Hallucinations typically appear 12-24 hours after the last intake (2-8% of patients), seizures at 12-48 hours (up to 15%), and delirium tremens approximately 72 hours after the last intake in 3-5%. Symptoms typically manifest within 8 hours of cessation, peak over 1 to 3 days, and can extend for up to 2 weeks. Without recognition or prompt treatment, DTs mortality can be as high as 50% — which is why this is an ICU problem.^[7]
Benzodiazepines first-line — the only class with seizure AND delirium data. Versus placebo, benzodiazepines reduce withdrawal seizures RR 0.16 (95% CI 0.04-0.69; Cochrane, 64 trials). In the 149-trial network meta-analysis (10,692 participants), fixed-schedule chlordiazepoxide (OR 0.21), lorazepam (OR 0.19), diazepam (OR 0.16) and divalproex (OR 0.22) each beat placebo for incident seizures — but only fixed-schedule diazepam reduced incident delirium tremens (OR 0.19, 95% CI 0.05-0.76). Diazepam and lorazepam are the preferred agents depending on regime and context; no single agent is proven superior.^[6]^[9]^[4]
Thiamine with or before glucose — the preventable disaster. Manage hypoglycaemia with concurrent thiamine to prevent Wernicke encephalopathy and subsequent Korsakoff syndrome. For ICU patients with chronic alcohol use disorder, the evidence-based day-1 formula is thiamine 200-500 mg IV every 8 hours with magnesium sulfate 64 mg/kg and folate 400-1000 mcg IV — abandon the reflexive banana bag, which likely under-delivers thiamine to the CNS. And treat empirically: in a necropsy-verified series only 16% of Wernicke-Korsakoff cases showed the classical triad and 80% were not diagnosed during life — if you suspect it, give parenteral thiamine.^[7]^[10]^[12]
Withdrawal seizures — benzodiazepines work; non-benzodiazepine anticonvulsants do not prevent them. Seizures strike 12 to 48 hours after the last intake in up to 15% of patients. Carbamazepine, oxcarbazepine, valproic acid and gabapentin have less abuse potential but DO NOT prevent withdrawal seizures; benzodiazepines are the recommendation (RR 0.16 vs placebo). The examiner trap is the word "prophylaxis" — only benzodiazepines deliver it.^[7]^[8]^[6]
CIWA-Ar — a validated 10-item severity scale, used serially. CIWA-Ar is the shortened 10-item Clinical Institute Withdrawal Assessment for Alcohol, Revised — validated for routine care and drug trials. Score-guided (symptom-triggered) dosing beat fixed-schedule in the randomized trial: median treatment 9 vs 68 hours, total chlordiazepoxide 100 vs 425 mg, equal efficacy. For escalation, know the cohort signal: among 8742 hospitalized adults, odds of high-intensity care rose above 1.0 once CIWA-Ar reached 24 — but sensitivity at that cut-point was only 0.12, so treat the trend, not a single number.^[1]^[2]^[13]
Phenobarbital — 10 mg/kg IV, and now with hospital-wide outcome data. A single IV dose of phenobarbital 10 mg/kg added to a symptom-guided lorazepam protocol cut ICU admission to 8% vs 25% (95% CI 4-32) with no excess adverse events. A hospital-wide 10 or 15 mg/kg weight-based IV order set (ED, acute care, ICU) delivered 4.2-5.0-point lower daily maximum CIWA-Ar at 24-96 hours, 30.1 hours shorter treatment and 2.2 days shorter stay — no intubation, restraint or mortality signal. This is the refractory rescue with the strongest modern evidence.^[3]^[15]
Magnesium and B vitamins — correct them, skip the kitchen sink. The ICU day-1 formula pairs thiamine with magnesium sulfate 64 mg/kg IV (approximately 4-5 g for most adults) and folate 400-1000 mcg IV; when treating Wernicke-Korsakoff syndrome, magnesium and other B-vitamin deficiencies should be considered and corrected. But there is NO available evidence supporting a multivitamin — prescribe what the evidence supports.^[10]^[11]
Exclude co-morbidity — the delirium may not be withdrawal alone. Assessment of DT includes assessment of withdrawal severity, evaluation of the delirium, and screening for underlying medical co-morbidities; liver disease is very common in DT patients and complicates the presentation, the treatment choice and the outcome. Work-up spans the differential — electrolyte abnormalities, trauma in the intoxicated patient, infection: CBC, metabolic panel, magnesium, CT brain where indicated.^[4]^[7]
Adjuncts stay adjuncts. When benzodiazepines are compared with other drugs, the trends favour benzodiazepines for seizure control, delirium control and severe life-threatening side effects. Barbiturates, ketamine and propofol are described as alternatives in severe withdrawal, and severe withdrawal may progress to intubation and mechanical ventilation — but the GABA-glutamate imbalance is treated first with benzodiazepines.^[6]^[7]
Treat the withdrawal, then treat the dependence. Effective treatment of the withdrawal episode is only the initial step in recovery — long-term success depends on facilitating the patient's entry into ongoing treatment. Liaise with addiction medicine BEFORE discharge; readmission with another (potentially worse) withdrawal is the default trajectory without it.^[8]^[7]

References15Show

[1]Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, 1989.PMID 2597811
[2]Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA, 1994.PMID 8046805
[3]Rosenson J, Clements C, Simon B, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med, 2013.PMID 22999778
[4]Grover S, Ghosh A Delirium Tremens: Assessment and Management. J Clin Exp Hepatol, 2018.PMID 30564004
[5]Day E, Bentham PW, Callaghan R, et al. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane Database Syst Rev, 2013.PMID 23818100
[6]Amato L, Minozzi S, Vecchi S, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev, 2010.PMID 20238336
[7]Meloy P, Rutz D, Bhambri A. Alcohol Withdrawal. J Educ Teach Emerg Med, 2025.PMID 39926251
[8]Muncie HL Jr, Yasinian Y, Oge' L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician, 2013.PMID 24364635
[9]Bahji A, Bach P, Danilewitz M, et al. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction, 2022.PMID 35194860
[10]Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med, 2016.PMID 27002274
[11]Dingwall KM, Delima JF, Binks P, et al. What is the optimum thiamine dose to treat or prevent Wernicke's encephalopathy or Wernicke-Korsakoff syndrome? Results of a randomized controlled trial. Alcohol Clin Exp Res, 2022.PMID 35428992
[12]Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry, 1986.PMID 3701343
[13]To DC, Steel TL, Carey KA, et al. Alcohol Withdrawal Severity Measures for Identifying Patients Requiring High-Intensity Care. Crit Care Explor, 2024.PMID 38505174
[14]Maldonado JR, Sher Y, Ashouri JF, et al. The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol, 2014.PMID 24657098
[15]Wolpaw BJ, Oren H, Quinnan-Hostein L, et al. Hospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol Withdrawal. JAMA Netw Open, 2025.PMID 40853658

Acute severe alcohol withdrawal and delirium tremens: CIWA-Ar, benzodiazepines, and Wernicke

Also known as Alcohol withdrawal · Delirium tremens · DTs · CIWA-Ar · Alcohol withdrawal syndrome · AWS

high15 referencesUpdated 26 July 202620 min readVerification in progress

Practise this topic

8 MCQs

Stage

Timing

Symptoms

Management

Minor withdrawal

6-24h (onset)

Tremor, agitation, anxiety, insomnia, nausea, sweating, vomiting, hallucinations, tachycardia, hypertension

Benzodiazepine, fixed-dose or symptom-triggered; give at symptom onset and continue until symptoms subside; thiamine; electrolytes^[8]

Alcoholic hallucinosis

12-24h (2-8%)

Hallucinations with the withdrawal syndrome

Benzodiazepine; supportive care^[7]

Withdrawal seizures

12-48h (up to 15%)

Generalised seizures during withdrawal

Benzodiazepines — seizures RR 0.16 vs placebo; carbamazepine, oxcarbazepine, valproate, gabapentin have less abuse potential but do NOT prevent withdrawal seizures^[6]^[8]

Delirium tremens (DTs)

typically ~72h (3-5%)

Potentially fatal encephalopathy: delirium with agitation, hallucinations, life-threatening autonomic dysfunction

ICU with continuous monitoring; benzodiazepines are the mainstay (diazepam or lorazepam); phenobarbital 10 mg/kg IV for refractory; exclude and treat underlying co-morbid illness incl. infection; severe withdrawal may progress to intubation and mechanical ventilation^[7]^[3]^[4]

Clinical pearls

References15Show

[1]Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, 1989.PMID 2597811
[2]Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA, 1994.PMID 8046805
[3]Rosenson J, Clements C, Simon B, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med, 2013.PMID 22999778
[4]Grover S, Ghosh A Delirium Tremens: Assessment and Management. J Clin Exp Hepatol, 2018.PMID 30564004
[5]Day E, Bentham PW, Callaghan R, et al. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. Cochrane Database Syst Rev, 2013.PMID 23818100
[6]Amato L, Minozzi S, Vecchi S, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev, 2010.PMID 20238336
[7]Meloy P, Rutz D, Bhambri A. Alcohol Withdrawal. J Educ Teach Emerg Med, 2025.PMID 39926251
[8]Muncie HL Jr, Yasinian Y, Oge' L. Outpatient management of alcohol withdrawal syndrome. Am Fam Physician, 2013.PMID 24364635
[9]Bahji A, Bach P, Danilewitz M, et al. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction, 2022.PMID 35194860
[10]Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med, 2016.PMID 27002274
[11]Dingwall KM, Delima JF, Binks P, et al. What is the optimum thiamine dose to treat or prevent Wernicke's encephalopathy or Wernicke-Korsakoff syndrome? Results of a randomized controlled trial. Alcohol Clin Exp Res, 2022.PMID 35428992
[12]Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry, 1986.PMID 3701343
[13]To DC, Steel TL, Carey KA, et al. Alcohol Withdrawal Severity Measures for Identifying Patients Requiring High-Intensity Care. Crit Care Explor, 2024.PMID 38505174
[14]Maldonado JR, Sher Y, Ashouri JF, et al. The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol, 2014.PMID 24657098
[15]Wolpaw BJ, Oren H, Quinnan-Hostein L, et al. Hospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol Withdrawal. JAMA Netw Open, 2025.PMID 40853658